Miami, FL, United States
Miami, FL, United States

Time filter

Source Type

News Article | October 28, 2016
Site: www.marketwired.com

MIAMI, FL--(Marketwired - October 28, 2016) - Dr. Sergio Gonzalez-Arias, chief of neurological surgery at Baptist Hospital and chair of the Department of Neuroscience at FIU's Herbert Wertheim College of Medicine, will join the College of Medicine's executive team as executive associate dean for clinical affairs. Gonzalez-Arias, who will begin his new position with the Herbert Wertheim College of Medicine in January 2017, will oversee all clinical functions at the College of Medicine, including the students' clinical experience; all strategic partnerships with hospitals and other clinical sites where students perform their clinical rotations; and development of Graduate Medical Education. "We have been fortunate to work with Dr. Gonzalez-Arias as a key member of our faculty since 2010. Now he brings to his new position a wealth of clinical experience that will add to the development of clinical programs to the College of Medicine," said Dr. John A. Rock, founding dean of the Herbert Wertheim College of Medicine and FIU senior vice president for health affairs. Wayne Brackin, executive vice president and chief operating officer for Baptist Health South Florida, said Gonzalez-Arias has made important contributions to the field of neuroscience. "Dr. Gonzalez-Arias is a well-respected neurosurgeon who has advanced his profession and expanded the comprehensive neuroscience offerings at Baptist Health," Brackin said. "As the founding medical director of Baptist Health Neuroscience Center he has developed and implemented surgical and technological advancements that have had a profound impact on our patients." Gonzalez-Arias is the founding and current medical director of Baptist Health Neuroscience Center. He has served as chief of Baptist Hospital's Department of Surgery and is a past president of the medical staff. He is a fellow of the American Association of Neurological Surgeons and the American College of Surgeons. He served as chair of the international committee of the Joint Council of State Neurosurgical Societies and is a past president of the Florida Neurological Society. "I am excited about this new opportunity at the FIU College of Medicine, which will allow me to continue building on its impressive growth, which I am honored to have been part of for several years," Gonzalez-Arias said. "In keeping with the best practice of a multidisciplinary approach to medicine, I look forward to collaborating with the university's hospital and community partners to research, innovate and continue making a significant positive impact on medical education and healthcare in our community." Dr. Gonzalez-Arias is a graduate of the University of Zaragoza (Spain) and completed his residencies at Rush-Presbyterian St. Luke's Medical Center and the University of Miami/Jackson Memorial Hospital. About Baptist Health South Florida: Baptist Health South Florida is the largest healthcare organization in the region, with seven hospitals (Baptist Hospital, Baptist Children's Hospital, Doctors Hospital, Homestead Hospital, Mariners Hospital, South Miami Hospital and West Kendall Baptist Hospital), nearly 50 outpatient and urgent care facilities, Baptist Health Medical Group, Baptist Health Quality Network and internationally renowned centers of excellence. The not-for-profit, faith-based Baptist Health has approximately 16,000 employees and 2,300 affiliated physicians. Baptist Health South Florida has been recognized as one of the 100 Best Companies to Work For in America and as one of the World's Most Ethical Companies. For more information, visit BaptistHealth.net and connect with us on Facebook at facebook.com/BaptistHealthSF and on Twitter and Instagram @BaptistHealthSF. About The FIU Herbert Wertheim College of Medicine: The Herbert Wertheim College of Medicine was approved in 2006 by the Florida Board of Governors and the Florida Legislature, and in February 2013 the medical degree program received full accreditation from the Liaison Committee for Medical Education. The College graduated its inaugural class on April 29, 2013. Among the innovative elements of the HWCOM is a program called Green Family Foundation NeighborhoodHELP™ that sends teams of medical students along with their counterparts in social work, nursing, and law into the community. The College of Medicine's mission is to lead the next generation of medical education and improve the quality of health care available to the South Florida community. For more information visit http://medicine.fiu.edu/ About FIU: Florida International University is classified by Carnegie as a "R1: Doctoral Universities - Highest Research Activity" and recognized as a Carnegie Community Engaged university. It is a public research university with colleges and schools that offers bachelor's, master's and doctoral programs in fields such as business engineering, computer science, international relations, architecture, law and medicine. As one of South Florida's anchor institutions, FIU contributes almost $9 billion each year to the local economy and is ranked second in Florida in Forbes Magazine's "America's Best Employers" list. FIU graduates are consistently among the highest paid college graduates in Florida and are among the leaders of public and private organizations throughout South Florida. FIU is Worlds Ahead in finding solutions to the most challenging problems of our time. FIU emphasizes research as a major component of its mission with multiple state-of-the-art research facilities including the Wall of Wind Research and Testing Facility, FIU's Medina Aquarius Program and the Advanced Materials Engineering Research Institute. FIU has awarded more than 220,000 degrees and enrolls more than 54,000 students in two campuses and centers including FIU Downtown on Brickell, FIU@I-75, the Miami Beach Urban Studios, and Tianjin, China. FIU also supports artistic and cultural engagement through its three museums: Patricia & Phillip Frost Art Museum, the Wolfsonian-FIU, and the Jewish Museum of Florida-FIU. FIU is a member of Conference USA and more than 400 student-athletes participating in 18 sports. For more information about FIU, visit http://www.fiu.edu/.


SHAPE, the Society for Heart Attack Prevention and Eradication (http://www.shapesociety.org), a nonprofit grassroots organization dedicated to the mission of eradicating heart attacks, today announced the agenda of its first focus group meeting on prediction of near-future heart attacks using artificial intelligence. The meeting is led by Dr. Morteza Naghavi the founder and executive director of SHAPE and features leading cardiovascular researchers from around the world.. This will be the 20th scientific meeting held by SHAPE since 2001. Detailed agenda of the meeting is shown below. The First Machine Learning Vulnerable Patient Symposium A Focus Group Meeting on Developing an Artificial Intelligence-based Forecast System A Satellite Event in Conjunction with 2016 Annual Scientific Sessions of American Heart Association This event is open to public. Participation via GoToMeeting can be requested. Dinner will be served 7:30 PM. This is the 20th Vulnerable Plaque & Vulnerable Patient Symposium held by SHAPE since 2001. Welcome: Morteza Naghavi, M.D. Founder of SHAPE and Executive Chairman of the SHAPE Task Force Opening Remarks: Valentin Fuster, M.D., Ph.D. Professor of Medicine and Physician-in-Chief, Mount Sinai Hospital and Icahn School of Medicine Jagat Narula M.D., Ph.D. Chief of Cardiology, Mount Sinai West & St. Luke’s Hospitals Associate, Dean, Arnhold Institute for Global Health at Mount Sinai Icahn School of Medicine Ioannis Kakadiaris, Ph.D. Professor of Computer Science and Biomedical Engineering, Director of Machine Learning Laboratory University of Houston Topic: What is Machine Learning and How Can It Shape the Future of Healthcare? Invited Online Presentations: Two Examples of Machine Learning Studies in CVD Risk Assessment (10 minutes each) CVD prediction using support vector machine in a large Australian cohort. Dinesh Kumar, Ph.D. and Sridhar Arjunan, Ph.D. Biosignals Lab, School of Electrical and Computer Engineering, RMIT University, Melbourne, Australia (2) Prediction of revascularization after myocardial perfusion SPECT by machine learning in a large clinical population Piotr Slomka, Ph.D. Chief Scientist, Artificial Intelligence in Medicine Program, Department of Imaging Cedars-Sinai Medical Center, Professor, UCLA School of Medicine, Los Angeles, CA Moderated Discussions on the Vulnerable Patient Project Machine Learning for Prediction of Near-Term CHD Events All investigators will be asked to give a very brief introduction of their study and how it can fit in Background: Imagine instead of the existing daily weather forecasts and hurricane alerts we were told the probability of a storm within the next 10 years! This is how heart attacks are predicted today. We teach our physicians to calculate the 10-year probability of a heart attack and sudden cardiac death based on their patients’ risk factors. Long term predictions do not trigger immediate preventive actions. Although some people develop warning symptoms, half of men and two-thirds of women who die suddenly of coronary heart disease (CHD) have no previous symptoms. Imagine if we could alert people months, weeks, or even days before a heart attack and trigger immediate preventive actions. The Idea: Use machine learning to create new algorithms to detect who will experience a CHD event within a year (The Vulnerable Patient). Algorithms will be based on banked biospecimen and information collected days up to 12 months prior to the event. We will utilize existing cohorts such as MESA, Heinz Nixdorf Recall Study, Framingham Heart Study, BioImage Study and the Dallas Heart Study. External validation to test for discrimination and calibration will be conducted using other longitudinal observational studies that provide adjudicated cardiovascular event information such as the MiHeart, JHS, DANRISK and ROBINSCA. Additionally, we will use machine learning to characterize individuals who, despite high conventional risk, have lived over 80 years with no CHD events (The Invulnerable ). We expect to discover new targets for drug and possibly vaccine development. We will make the algorithms available as an open source tool to collect additional data over time and increase its predictive value. Organizers: SHAPE as the originating and organizing center for the entire project, recruiting new studies and biobanks, conducting workshops with researchers from each study, fundraising, creating an open source platform community for future enhancement and collaborations. Stanford as the coordinating center for collecting data and samples, and basic science labs. Mount Sinai as the data review and publication center. Machine Learning Lab to be decided, either Google, Apple, IBM, Facebook, Amazon or wherever we find a strong industry partner or sponsor. Director, Cardiac Computed Tomography, Associate Professor of Medicine, Johns Hopkins University Division of Cardiology, The Johns Hopkins Hospital Imagine the new machine learning Vulnerable Patient detection algorithm (heart attack forecaster) is created and validated. If studies confirm the algorithm is able to detect the Vulnerable Patient with 50% or more certainty. In other words, 1 out of 2 patients classified as Vulnerable Patient goes to have an ASCVD event in the following 12 months. Now the questions are: A)    What preventive actions would you take if your asymptomatic patient tested positive as a Vulnerable Patient? B)    What preventive actions would you take if the patient was you?! (This question is meant to circumvent regulatory and financial limitations that may apply to your patients but may not hold you back). Moderators will invite comments from all participants in the meeting. Invited Key Opinion Leaders (Alphabetic Order) Arthur Agatston, M.D. Founder of South Beach Diet, Director of Wellness at Baptist Hospital and Professor of Medicine at University of Miami, FL Daniel Berman, M.D. Professor of Medicine at UCLA, Director of Cardiac Imaging and Nuclear Cardiology at Cedars-Sinai, Los Angeles, CA Michael Blaha, M.D., M.P.H., Director of Clinical Research, Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University, Baltimore, MD Mathew Budoff, M.D. Professor of Medicine and Director of Preventive Cardiology, UCLA Harbor, Los Angeles, CA Adolfo Correa, M.D., Ph.D. Chief Science Officer, Jackson Heart Study, Professor of Medicine and Pediatrics, University of Mississippi, Jackson, MS Rahul Deo, M.D., Ph.D. Assistant Professor of Medicine, Division of Cardiology, University of California, San Francisco, CA Raimund Erbel, M.D. Professor of Medicine, Chief of Cardiology and Director of West German Heart Centre, University Essen, Germany Sergio Fazio, M.D., Ph.D. Chair of Preventive Cardiology and Professor of Medicine, Oregon Health and Science University, Portland, OR Zahi Fayad, M.D. Professor of Radiology and Medicine (Cardiology), Director of the Translational and Molecular Imaging Institute, Mount Sinai Hospital, New York, NY Philip Greenland, M.D., Professor of Cardiology, Director, Institute for Public Health and Medicine, Center for Population Health Sciences, Chicago, IL Robert Harrington, M.D. Chair of the Department of Medicine, Professor of Medicine, Stanford University School of Medicine, Stanford, CA Harvey Hecht, M.D., Director of Cardiac CT Imaging Laboratory, Mount Sinai School of Medicine, New York, NY Karl-Heinz Jöckel, Ph.D. Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Germany Ioannis Kakadiaris, Ph.D. Professor of Computer Science and Biomedical Engineering, University of Houston, Houston, TX Stanley Kleis, Ph.D. Professor of Mechanical Engineering and Biomedical Engineering, University of Houston, Houston, TX Tatiana Kuznetsova, M.D. Professor and Director, Hypertension and Cardiovascular Epidemiology, University of Leuven, Leuven, Belgium Daniel Levy, M.D. Director of Framingham Heart Study, and Intramural Investigator, National Institute of Health, Bethesda, MD Roxana Mehran, M.D. Professor of Medicine and Director of Interventional Clinical Trials, Mount Sinai School of Medicine, New York, NY Ralph Metcalfe, Ph.D. Professor of Mechanical and Biomedical Engineering, University of Houston, Houston, TX Susanne Moebus, Ph.D., M.P.H. Biologist & Epidemiologist, Head of the Centre for Urban Epidemiology, University Essen, Germany Morteza Naghavi, M.D. Founder and Executive Chairman of the SHAPE Task Force, President of MEDITEX, Houston, TX Tasneem Z. Naqvi, M.D. Professor of Medicine and Director of Echocardiography, College of Medicine, May Clinic, Scottsdale, AZ Jagat Narula, M.D., Ph.D. Associate Dean for Global Affairs, Professor of Medicine (Cardiology), Mount Sinai Hospital and School of Medicine, New York, NY Ulla Roggenbuck, Ph.D. Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, Germany Henrik Sillesen, M.D. Professor and Head of Dept. of Vascular Surgery, Rigs Hospitalet, University of Copenhagen, Copenhagen, Denmark Robert Superko, M.D. Professor of Medicine and President at Cholesterol, Genetics, and Heart Disease Institute, Carmel, CA Pierre-Jean Touboul, M.D. Professor of Neurology, Department of Neurology and Stroke Center, AP-HP Bichat University Hospital, Neurology and Stroke Center, Paris, France Nathan Wong, M.P.H., Ph.D. Professor of Epidemiology and Director, Heart Disease Prevention Program, University of California, Irvine, CA Symposium Registration http://shapesociety.org/the-first-machine-learning-heart-attack-forecast-symposium/ About SHAPE The Society for Heart Attack Prevention and Eradication (SHAPE) is a non-profit organization that promotes education and research related to prevention, detection, and treatment of heart attacks. SHAPE is committed to raising public awareness about revolutionary discoveries that are opening exciting avenues that can lead to the eradication of heart attacks. SHAPE's mission is to eradicate heart attacks in the 21st century. SHAPE has recently embarked on “Machine Learning Heart Attack Forecast System (Vulnerable Patient Project)” Project which is a collaborative effort between world’s leading cardiovascular researchers to develop a new Heart Attack Forecast System empowered by artificial intelligence. Additional information on this innovative project will be announced soon. To learn more about SHAPE visit http://www.shapesociety.org. Contact information: 1-877-SHAPE11 and info(at)shapesociety(dot)org. Learn more about the Vulnerable Patient http://shapesociety.org/the-first-machine-learning-heart-attack-forecast-symposium About SHAPE Task Force The SHAPE Task Force, an international group of leading cardiovascular physicians and researchers, has created the SHAPE Guidelines, which educates physicians on how to identify asymptomatic atherosclerosis (hidden plaques) and implement proper therapies to prevent a future heart attack. According to the SHAPE Guidelines, men 45-75 and women 55-75 need to be tested for hidden plaques in coronary or carotid arteries. Individuals with high risk atherosclerosis (high plaque score) should be treated even if their cholesterol level is within statistical “normal range.” If they have plaques, the so-called normal is not normal for them. The higher the amount of plaque burden in the arteries the higher the risk and the more vulnerable to heart attack. SHAPE Guideline aims to identify the asymptomatic “Vulnerable Patient” and offer them intensive preventive therapy to prevent a future heart attack. Knowing one's plaque score can be a matter of life and death. The SHAPE Task Force includes the following: Click below to learn about SHAPE Centers of Excellence http://shapesociety.org/centers-of-excellence/ Drs Naghavi, PK Shah, Daniel Berman, and Mathew Budoff members of the SHAPE Task Force explain how hospitals and community clinics can become a SHAPE Center of Excellence and establish themselves a leader in preventive health.


News Article | February 22, 2017
Site: globenewswire.com

NEW YORK, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Dr. Sharon Metcalfe, Interim Director of Nursing at Western Carolina University, has been selected to join the Education Board at the American Health Council. She will be sharing her knowledge and expertise on Nursing Education and Clinical / Didactic Testing. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0ead4c6b-51d4-40e9-90ea-cb328bbfeb1a With over a decade of experience in the field of Nursing Education, Dr. Metcalfe offers valuable insight in her role as the Interim Director of Nursing at Western Carolina University. Located in Cullowhee, North Carolina, Western Carolina University is a public regional institution of higher education that is committed to offering quality education at an affordable rate.  Ranked as one of the top fifteen public regional institutions in the South, WCU give prospective students an opportunity to choose from more than a hundred and fifteen majors and concentrations ranging from Biology, Computer Information Systems, Spanish, Business Administration and much more. As the Interim Director of Nursing at Western Carolina University, Dr. Metcalfe’s day-to-day responsibilities include oversight of programs and forty facilities, management of scholarships, the university budget, and community groups. Prior to her role as the Interim Director, Dr. Metcalfe gained leadership experience as the Dean of Nursing for at Lees-McRae College and Mayland Community College. In the clinical setting, Dr. Metcalfe has served as the Director of Pediatrics (Denver, Colorado Children's Hospital), Director of Neonatal Services at Rose Medical Center (Denver, Colorado), and Nursing Administrator of Pediatrics, Critical Care, Intensive Care, and Neonatal Intensive Care at Wake Forest Medical Center-Baptist Hospital (Winston-Salem, North Carolina). In 1997, Dr. Metcalfe earned her Doctorate of Education in Adult and Community College Education from the North Carolina State University. She went on to complete a Bachelor of Science in Nursing degree and receive certification as a Registered Nurse from the University of Colorado. Dr. Metcalfe maintains affiliations with the North Carolina Nurses Association and Sigma Theta Tao. She serves on the Board of Directors for the Mountain Area Health Education Minority and Underrepresented Students Council, and the Board of Directors for the Social Services division of Asheville, North Carolina. Dr. Metcalfe’s desire to pursue Nursing Education developed through a natural progression. Looking back, she attributes her success to her supportive husband Lee and her loving son Trevor. Due to her commitment and dedication to the field of Nursing Education, Dr. Metcalfe has been awarded the 2016 Health Science College Award, 2006 100 Best Nurses Award, and 2005 Native American Teacher of the Year. Among her many accomplishments, Dr. Metcalfe has published three significant articles on mentoring, social determinants and educational barriers for diverse students, and the nature of cultural competency. In her free time, she enjoys traveling to Europe. As a certified Parent Child Interventionist, Dr. Metcalfe volunteers her time being a high risk parenting educator for the Department of Social Work conducting seminars for foster parents that struggle with difficult children during the fall of each year. Considering her future, Dr. Metcalfe hopes for continual growth in research, and education by teaching a RN to BSN program.


News Article | November 20, 2016
Site: www.prweb.com

Dr. Carlos Wolf, premier facial plastic surgeon of Miami, FL has joined the prestigious Haute Beauty network. The Haute Beauty Network, affiliated with luxury lifestyle publication Haute Living, is proud to recognize Dr. Carlos Wolf as a prominent facial plastic surgeon and the network’s newest partner. Dr. Carlos Wolf is a double board certified in Facial Plastic and Reconstructive Surgery as well as in Otolaryngology. He is a member of the American Medical Association, Sigma XI Honorary Scientific Society, Florida Medical Society, and Dade County Medical Society. Dr. Wolf will share his skill and expert opinion with the Haute Beauty and Haute Living subscribers, educating readers on his industry and providing exciting and relevant news, tips, trends and insight relating to his specialties. Dr. Wolf began practicing in 1984 and in 1999 merged with Dr. Michael Kelly to create Miami Plastic Surgery. Being the warm, welcoming man that he is, Dr. Wolf’s patients always feel at home and confident in his care. They consistently refer their closest family and friends to his practice with the assurance that he will achieve extraordinary, yet natural and unique, results for each and every one of them. While his skills are second-nature to him, Dr. Wolf continues to acquire new techniques that allow him to achieve the best result for each patient he sees. No matter how long Dr. Wolf has been in practice and how many patients he has seen, he is still just as excited with each and every case. Just as no two patients are the same, no two surgeries are the same. This is one of Dr. Wolf’s favorite aspects to his practice. He prides himself on personalizing each and every case to ensure he is achieving the best result for that particular patient. In Dr. Wolf’s opinion, plastic surgery should be invisible, and he successfully strives for and achieves a natural result with each case. Dr. Wolf is one of the most prestigious facial plastic surgeons in the country and one of America’s Most Honored Professionals according to The American Registry. He is one of the greats among the greatest facial plastic surgeons in the United States. Through his weekly segment on Telemundo’s Un Nuevo Dia, bi-weekly column in the Miami Herald, and numerous guest editorial contributions Dr. Wolf has become a nationally trusted expert in all things cosmetic. Privacy, safety, and comfort are of supreme importance to Dr. Wolf. All procedures are performed in Miami Plastic Surgery’s elite, fully accredited O.R. Suite which is located in Baptist Hospital’s Medical Arts Building, with only board-certified staff anesthesiologists from Baptist hospital. Having privileges at Baptist Hospital, Dr. Wolf is able to perform surgeries in the hospital as well. From consultation to post-operative follow ups Dr. Wolf and his team are there to support his patients and ensure their confidence and comfort.


News Article | March 2, 2017
Site: www.businesswire.com

MIAMI--(BUSINESS WIRE)--Miami Cardiac & Vascular Institute has completed its $120 million expansion project on the Baptist Hospital campus. The state-of-the-art facility includes additional space and cutting-edge technology, facilitating the creation of several new, specialized programs bringing together multidisciplinary teams of specialists to treat the cardiovascular system as a single entity. The expansion added 60,000 square feet of new space and included 40,000 square feet of renovations, nearly doubling the size of the Institute to 150,000 square feet in order to accommodate a growing number of patients and procedures. Since it was founded in 1987, Institute physicians have pioneered less-invasive techniques to treat aneurysms, stroke and heart disease, and have been part of many groundbreaking research trials. For 30 years, Miami Cardiac & Vascular Institute has been an integral innovation partner for Philips, a world leader in healthcare technologies, providing valuable clinical insights that have led to the development of industry-leading solutions such as the recently announced Philips Azurion Image Guided Therapy (IGT) system. The expansion includes a state-of-the-art Cath lab, representing the first North American installation of Azurion. The system is designed to anticipate what clinicians need, when they need it, to make procedures flow intuitively and support a superior patient experience. “This expansion allows us to be at the forefront of medical innovation and provides the most current treatment options for our patients, while at the same time, prepares us to be in the position to care for health problems we haven’t even encountered yet,” said Barry T. Katzen, M.D., Chief Medical Executive and founder of the Institute. “We are now able to conduct more research, offer new services and make discoveries that could transform how cardiovascular care is delivered.” Throughout its history, the Institute’s physicians have pioneered less-invasive techniques to treat aneurysms, stroke and heart disease, and have been part of many groundbreaking research trials. The newly expanded Institute, with its cutting-edge equipment and unique programs, allows our internationally respected physicians to continue their visionary work. One of the first elements of the three-year project was the expansion of Baptist Hospital’s Surgery Center, which now includes six large operating rooms dedicated to neuroscience, cardiac, vascular and robotic surgery. The Institute also added four new advanced endovascular suites with enlarged gallery viewing areas for enhanced teaching and learning opportunities. “This is the centerpiece of the expansion, the Center for Advanced Endovascular Therapies,” Dr. Katzen explained. “We wanted to create an environment in which we could do any type of predominantly image-guided procedure, where physicians of different disciplines could work together to create unique solutions for patients’ problems.” In designing interventional suites of the future, two of the new endovascular suites have glass walls and a video system that allow people to sit in a theater-style chair outside of the suite and control what they are watching using an iPad. Viewers from different disciplines or in training each can have their own unique user interface that allows them to pick and choose which parts of the procedure they want to watch, all with communication with the suites. Additionally, the Institute makeover created the National Center for Aneurysm Therapy — the first in the world — a Center for Structural Heart Therapy, Center for Critical Limb Ischemia and an Advanced Arrhythmia Therapy Center. It is here where physicians are doing research to discover more cardiovascular disease breakthroughs. “We are proud to open the doors of the new Miami Cardiac & Vascular Institute to our community,” said Brian E. Keeley, President and CEO of Baptist Health South Florida. “This expansion now provides even greater promise to our patients, with new state-of-the-art interventional procedure suites; an expansive, high-tech gallery for observation, diagnostics and greater teaching opportunities; and, research space for more than 120 clinical trials.” Miami Cardiac & Vascular Institute is the largest and most comprehensive cardiovascular facility in the region, consisting of 76 doctors and 1,100 employees system-wide serving 125,000 patients every year. “At Philips, we are committed to building a healthy society by creating solutions that are going to have a meaningful impact in improving human health, and this requires collaboration with pioneering organizations like Miami Cardiac & Vascular Institute,” said Brent Shafer, CEO of Philips North America. “The Institute’s clinical insights have been critical to the development of our Azurion technology, from understanding workflows and improving efficiencies, to understand how to improve the patient experience. Together, we are shaping the future of healthcare by making procedures safer and more efficient. This will not only help address the health issues in South Florida communities, it will allow us to apply those lessons globally to help tackle the challenges of rising healthcare costs and better access to care. Ultimately, we want to improve the patient experience and outcomes, one community at a time.” Miami Cardiac & Vascular Institute is the largest and most comprehensive cardiovascular facility in the region. The team of multilingual, multidisciplinary specialists has pioneered the development of minimally invasive techniques used to treat aneurysms, blockages in veins and arteries and holes in the heart. Miami Cardiac & Vascular Institute is part of Baptist Health South Florida, the largest healthcare organization in the region, with seven hospitals (Baptist Hospital, Baptist Children’s Hospital, Doctors Hospital, Homestead Hospital, Mariners Hospital, South Miami Hospital and West Kendall Baptist Hospital), nearly 50 outpatient and urgent care facilities, Baptist Health Medical Group, Baptist Health Quality Network and internationally renowned centers of excellence. The not-for-profit, faith-based Baptist Health has approximately 16,000 employees and 2,300 affiliated physicians. Baptist Health South Florida has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies. For more information, visit BaptistHealth.net and connect with us on Facebook at facebook.com/BaptistHealthSF and on Twitter and Instagram @BaptistHealthSF. Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.


News Article | March 2, 2017
Site: www.marketwired.com

MIAMI, FL--(Marketwired - March 02, 2017) - Miami Cardiac & Vascular Institute has completed its $120 million expansion project on the Baptist Hospital campus. The state-of-the-art facility includes additional space and cutting-edge technology, facilitating the creation of several new, specialized programs bringing together multidisciplinary teams of specialists to treat the cardiovascular system as a single entity. The expansion added 60,000 square feet of new space and included 40,000 square feet of renovations, nearly doubling the size of the Institute to 150,000 square feet in order to accommodate a growing number of patients and procedures. Since it was founded in 1987, Institute physicians have pioneered less-invasive techniques to treat aneurysms, stroke and heart disease, and have been part of many groundbreaking research trials. For 30 years, Miami Cardiac & Vascular Institute has been an integral innovation partner for Philips, a world leader in healthcare technologies, providing valuable clinical insights that have led to the development of industry-leading solutions such as the recently announced Philips Azurion Image Guided Therapy (IGT) system. The expansion includes a state-of-the-art Cath lab, representing the first North American installation of Azurion. The system is designed to anticipate what clinicians need, when they need it, to make procedures flow intuitively and support a superior patient experience. "This expansion allows us to be at the forefront of medical innovation and provides the most current treatment options for our patients, while at the same time, prepares us to be in the position to care for health problems we haven't even encountered yet," said Barry T. Katzen, M.D., Chief Medical Executive and founder of the Institute. "We are now able to conduct more research, offer new services and make discoveries that could transform how cardiovascular care is delivered." Throughout its history, the Institute's physicians have pioneered less-invasive techniques to treat aneurysms, stroke and heart disease, and have been part of many groundbreaking research trials. The newly expanded Institute, with its cutting-edge equipment and unique programs, allows our internationally respected physicians to continue their visionary work. One of the first elements of the three-year project was the expansion of Baptist Hospital's Surgery Center, which now includes six large operating rooms dedicated to neuroscience, cardiac, vascular and robotic surgery. The Institute also added four new advanced endovascular suites with enlarged gallery viewing areas for enhanced teaching and learning opportunities. "This is the centerpiece of the expansion, the Center for Advanced Endovascular Therapies," Dr. Katzen explained. "We wanted to create an environment in which we could do any type of predominantly image-guided procedure, where physicians of different disciplines could work together to create unique solutions for patients' problems." In designing interventional suites of the future, two of the new endovascular suites have glass walls and a video system that allow people to sit in a theater-style chair outside of the suite and control what they are watching using an iPad. Viewers from different disciplines or in training each can have their own unique user interface that allows them to pick and choose which parts of the procedure they want to watch, all with communication with the suites. Additionally, the Institute makeover created the National Center for Aneurysm Therapy -- the first in the world -- a Center for Structural Heart Therapy, Center for Critical Limb Ischemia and an Advanced Arrhythmia Therapy Center. It is here where physicians are doing research to discover more cardiovascular disease breakthroughs. "We are proud to open the doors of the new Miami Cardiac & Vascular Institute to our community," said Brian E. Keeley, President and CEO of Baptist Health South Florida. "This expansion now provides even greater promise to our patients, with new state-of-the-art interventional procedure suites; an expansive, high-tech gallery for observation, diagnostics and greater teaching opportunities; and, research space for more than 120 clinical trials." Miami Cardiac & Vascular Institute is the largest and most comprehensive cardiovascular facility in the region, consisting of 76 doctors and 1,100 employees system-wide serving 125,000 patients every year. "At Philips, we are committed to building a healthy society by creating solutions that are going to have a meaningful impact in improving human health, and this requires collaboration with pioneering organizations like Miami Cardiac & Vascular Institute," said Brent Shafer, CEO of Philips North America. "The Institute's clinical insights have been critical to the development of our Azurion technology, from understanding workflows and improving efficiencies, to understand how to improve the patient experience. Together, we are shaping the future of healthcare by making procedures safer and more efficient. This will not only help address the health issues in South Florida communities, it will allow us to apply those lessons globally to help tackle the challenges of rising healthcare costs and better access to care. Ultimately, we want to improve the patient experience and outcomes, one community at a time." Miami Cardiac & Vascular Institute is the largest and most comprehensive cardiovascular facility in the region. The team of multilingual, multidisciplinary specialists has pioneered the development of minimally invasive techniques used to treat aneurysms, blockages in veins and arteries and holes in the heart. Miami Cardiac & Vascular Institute is part of Baptist Health South Florida, the largest healthcare organization in the region, with seven hospitals (Baptist Hospital, Baptist Children's Hospital, Doctors Hospital, Homestead Hospital, Mariners Hospital, South Miami Hospital and West Kendall Baptist Hospital), nearly 50 outpatient and urgent care facilities, Baptist Health Medical Group, Baptist Health Quality Network and internationally renowned centers of excellence. The not-for-profit, faith-based Baptist Health has approximately 16,000 employees and 2,300 affiliated physicians. Baptist Health South Florida has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World's Most Ethical Companies. For more information, visit BaptistHealth.net and connect with us on Facebook at facebook.com/BaptistHealthSF and on Twitter and Instagram @BaptistHealthSF. Royal Philips (NYSE: PHG) (AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.


News Article | February 16, 2017
Site: www.24-7pressrelease.com

BEREA, KY, February 16, 2017-- Irene H. Lamb has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.Deeply committed to the medical community, Ms. Lamb is noted for her involvement with medical research at a time when that was uncommon for women. She is credited with helping to establish the first coronary care center in the United States, among many other professional accomplishments. In recognition of her contributions to medicine and science, Ms. Lamb has been featured in a wide range of honors publications, including Who's Who in America, Who's Who of American Women, Who's Who in the South and Southwest, Who's Who in Medicine and Healthcare, Who's Who in Science and Engineering, and Who's Who in the World. In addition, she was selected for inclusion in the 32nd and 33rd editions of Who's Who in Finance and Industry, as well as the 4th and 5th editions of Who's Who in American Nursing.A Registered Nurse residing in Kentucky, Ms. Lamb began a medical career upon receiving a diploma in nursing from the Kentucky Baptist Hospital. She had frequently attended Berea College working towards a biology degree and completed additional training at California State University in Los Angeles. During this time, Ms. Lamb assisted the University of Southern California and Los Angeles County Medical Center as a staff nurse and researcher. She has held various additional roles throughout the course of her career, including charge nurse and head nurse of acute medicine in a wide range of departments and medical centers, such as the medical intensive care unit, surgical intensive care unit and emergency room. In 1969, Ms. Lamb became the nurse manager of the clinical research center at the University of Southern California and Los Angeles County Medical Center. She remained in this position for five years before joining the Stanford University School of Medicine as a senior research nurse in the field of cardiology. In 1989, Ms. Lamb rose to the rank of director of clinical research with the San Diego Cardiac Center.Ms. Lamb has held a keen interest in stroke research since the turn of the century. From 1997 to 2002, she served as the senior of clinical research and manager of the stroke program with the University of Kentucky College of Medicine, located in Lexington. In addition, she was a member of the board of directors with the Kentucky Stroke Association from 1998 to 2000. An accomplished author, Ms. Lamb has contributed articles to professional journals and chapters to medical books.About Marquis Who's Who :Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America , Marquis Who's Who has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis now publishes many Who's Who titles, including Who's Who in America , Who's Who in the World , Who's Who in American Law , Who's Who in Medicine and Healthcare , Who's Who in Science and Engineering , and Who's Who in Asia . Marquis publications may be visited at the official Marquis Who's Who website at www.marquiswhoswho.com


Renshaw A.A.,Baptist Hospital | Elsheikh T.M.,Cleveland Clinic
American Journal of Clinical Pathology | Year: 2013

Previous prospective studies have shown different results when comparing automated and manual screening of gynecologic cytology. The results of 3 large prospective studies were reviewed and relative sensitivity used as a gold standard. No significant differences could be shown in relative sensitivity between the ThinPrep Imaging System and the FocalPoint GS Imaging System (P > .05). When manual screening was restricted to less than 6 hours per day, 50 or fewer slides per day, and at least 6 minutes per slide (<10 slides/h), the relative sensitivity for automation was significantly lower for atypical squamous cells of undetermined significance and above (ASC+) (0.81; 95% confidence interval [CI], 0.79- 0.83) than when manual screening was not restricted (1.07; 95% CI, 1.03-1.10). All 3 sites that screened 10 or more slides per hour manually had a relative sensitivity for automation that was significantly higher for high-grade squamous intraepithelial lesions and above (HSIL+) than for the remaining groups who screened less than 10 slides per hour (1.40 [95% CI, 1.22-1.60] vs 0.97 [95% CI, 0.95-1.00]). These results suggest that location finding of abnormalities (ASC+) may be more strongly associated with time spent screening per day, whereas classification/interpretation skills (HSIL+) may depend on time spent on an individual case. There is no evidence that automated screening devices are more sensitive than manual screening performed at lower well-defined workloads. More restricted workloads (=41 slides/d, =4.5 h/d) for manual screening may perform significantly better than automated screening devices as measured by histologic cervical intraepithelial neoplasia 2 and above. © American Society for Clinical Pathology.

Loading Baptist Hospital collaborators
Loading Baptist Hospital collaborators